Agitated Solutions Inc

Marani Health Inc is an AI-powered maternal healthcare platform based in St. Paul, MN, dedicated to enhancing the pregnancy experience for individuals and their care teams through connected devices and remote patient monitoring. The company aims to set a new standard in pregnancy care by providing vital insights that improve patient outcomes and streamline clinical workflows. Marani Health serves a diverse clientele, including maternity providers, health plans, and employers, by offering evidence-based personalized care and 24/7 support during the prenatal and postpartum journey. Through innovative technology and partnerships, Marani Health is committed to revolutionizing maternal and child health care while reducing overall costs for employers and enhancing the quality of care for patients. Generated from the website

Alpheus Medical, Inc., based in Chanhassen, Minnesota, is at the forefront of developing an innovative non-invasive therapy aimed at treating aggressive brain tumors, specifically glioblastoma multiforme (GBM). Their proprietary sonodynamic therapy utilizes ultrasound to activate a drug that targets cancer cells, addressing the diffuse nature of this complex disease beyond the visible tumor boundaries. The company's investigational treatment allows patients to remain awake during the procedure and return home the same day, marking a significant shift in brain tumor management. Alpheus Medical collaborates with leading experts in neuro-oncology and receives support from notable cancer research organizations to advance its groundbreaking treatment platform. Generated from the website

InSitu Biologics, Inc. is an emerging biotech company based in St. Paul, MN, dedicated to developing a multiphase prolonged release drug delivery platform aimed at localized treatment for pain, cancer, and infection. The company employs disruptive technology to address unmet needs in the pain management and drug delivery markets. Currently in the investigational preclinical stage, InSitu Biologics is advancing two key products: INSB200, an extended release solution for perioperative pain management, and INSB400, an early development product designed for the local delivery of cancer drugs with a precise elution rate. These innovative solutions represent a multibillion-dollar opportunity as the company approaches Phase 1 clinical trials. Generated from the website